01
Company overview
Bosnalijek d.d. is the largest pharmaceutical manufacturer in Bosnia and Herzegovina and one of the most established producers in Southeast Europe. Founded in Sarajevo in 1951, the company develops, manufactures and markets a broad portfolio of prescription medicines, over-the-counter products and food supplements. The company is built on its own research and development — more than ten new products are launched annually from in-house R&D, and the portfolio today spans 213 products based on 131 active substances. Bosnalijek operates an export-led model: over 70% of sales are generated outside Bosnia and Herzegovina, across 32 markets on four continents. Manufacturing is certified to EU GMP and, since 2024, US FDA standards. Shares trade on the Sarajevo Stock Exchange (BSNLR), where Bosnalijek ranks among the five most liquid stocks and is a constituent of the SASX-10 index.
02
The KBC position
KBC Euro Credit Capital Limited is the largest single shareholder of Bosnalijek d.d., holding approximately 23.67% of the company's share capital. The position makes KBC the reference shareholder in one of the region's most respected industrial assets, ahead of AS Holding d.o.o. (19.0%) and the custodial and institutional holders that follow. The remaining capital is widely distributed across more than 5,100 registered holders, giving Bosnalijek a broad free float and consistent trading liquidity on the SASE. For KBC, the holding represents a long-term strategic investment in a cash-generative, export-oriented pharmaceutical platform with a multi-decade operating history.
03
Financial performance
Bosnalijek has delivered consistent profitability and an uninterrupted dividend record. Total revenue reached a company record of roughly KM 202 million in 2022, with KM 187.3 million in 2023 and approximately €116 million in 2025. Net profit before tax exceeded KM 18.6 million in 2025, up materially year-on-year, supported by an optimised sales mix and disciplined pricing. Dividends of KM 1.10 per share were declared for 2023 and 2025, distributing roughly KM 10 million annually to shareholders. The combination of defensive healthcare demand, real manufacturing assets and export diversification gives the holding low correlation to financial-market cycles.
04
Operations & capacity
Since 1996, Bosnalijek has invested more than €150 million in construction, equipment, development and digitalisation. Manufacturing runs across two integrated plants in Sarajevo: solid oral forms (7,500 m², 42m packs/yr, 90% utilisation, three shifts) and non-sterile semi-solid and liquid forms (5,000 m², 25.5m packs/yr, 55% utilisation, three shifts). Combined capacity reaches 67.5 million packs per year. The semi-solid plant carries meaningful headroom for organic growth and contract-manufacturing partnerships without major new capital expenditure. Quality systems span ISO 9001/14001/45001/13485, EU, Turkish and Russian GMP, and US FDA approval since 2024. An automated high-bay warehouse is fully integrated with SAP ERP across development, production and logistics.
05
Markets & portfolio
Bosnalijek sells in 32 markets worldwide. Exports account for more than 70% of revenue, led historically by the Russian Federation and spanning the Adriatic region, the wider Eurasian corridor (Kazakhstan, Azerbaijan, Georgia), the Middle East (Iraq, Kuwait, Qatar, Yemen), parts of the EU and selected African and Asian markets. Around 90% of revenue is B2C — high-quality medicines for patients and healthcare professionals worldwide — with 10% in B2B contract manufacturing and out-licensing leveraging EU- and FDA-grade facilities. The portfolio is anchored by Lysobact®, the global leader in pharmaceutical-grade lysozyme therapeutics, complemented by 10+ new launches each year from in-house R&D.
06
Why KBC holds Bosnalijek
Market leadership (the clear #1 pharmaceutical manufacturer in BiH with a 75-year operating history); export diversification across 32 markets and four continents reducing single-economy dependence; an own R&D engine delivering 10+ launches annually; EU GMP and US FDA credentials opening higher-value regulated markets; and consistent profitability with an uninterrupted dividend record. Key considerations include historical reliance on the Russian Federation as the largest single export market, sensitivity to FX and input-cost cycles, ordinary regulatory pressure across multiple jurisdictions, and shareholder dynamics typical of a SASX-10-listed company on a smaller exchange.